Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy

Can J Gastroenterol Hepatol. 2018 Jul 16:2018:4671590. doi: 10.1155/2018/4671590. eCollection 2018.

Abstract

Background: Post-TIPS hepatic encephalopathy (PSE) is a complex process involving numerous risk factors; the root cause is unclear, but an elevation of blood ammonia due to portosystemic shunt and metabolic disorders in hepatocytes has been proposed as an important risk factor.

Aims: The aim of this study was to investigate the impact of pathological features of mitochondrial ultrastructure on PSE via transjugular liver biopsy at TIPS implantation.

Methods: We evaluated the pathological damage of mitochondrial ultrastructure on recruited patients by the Flameng classification system. A score ≤2 (no or low damage) was defined as group A, and a score >2 (high damage level) was defined as group B; routine follow-up was required at 1 and 2 years; the incidence of PSE and multiple clinical data were recorded.

Results: A total of 78 cases in group A and 42 in group B completed the study. The incidence of PSE after 1 and 2 years in group B (35.7% and 45.2%, respectively) was significantly higher than that in group A (16.7% and 24.4%, respectively); the 1- and 2-year OR (95% CI) were 2.778 (1.166-6.615) and 2.565 (1.155-5.696), respectively, for groups A and B. Importantly, group B had worse incidence of PSE than group A [P=0.014, hazard ratio (95%CI): 2.172 (1.190-4.678)].

Conclusion: Aggressive damage to mitochondrial ultrastructure in liver shunt predicts susceptibility to PSE. The registration number is NCT02540382.

MeSH terms

  • Adult
  • Aged
  • Biopsy, Needle
  • Cohort Studies
  • Disease Susceptibility / pathology*
  • Esophageal and Gastric Varices / complications
  • Esophageal and Gastric Varices / pathology
  • Female
  • Hepatic Encephalopathy / etiology
  • Hepatic Encephalopathy / pathology
  • Hepatic Encephalopathy / surgery*
  • Humans
  • Hypertension, Portal / complications
  • Hypertension, Portal / pathology
  • Hypertension, Portal / surgery*
  • Immunohistochemistry
  • Liver / pathology
  • Liver / ultrastructure
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / pathology
  • Liver Cirrhosis / surgery*
  • Male
  • Middle Aged
  • Mitochondria / ultrastructure*
  • Portasystemic Shunt, Transjugular Intrahepatic / adverse effects*
  • Predictive Value of Tests
  • Prospective Studies
  • Risk Assessment
  • Survival Rate
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT02540382